📌Session Update

🩸Our Multiple Myeloma session, previously postponed, has now been scheduled for April 10th!

🔗Register: hemehub.org/live-webinars
🔗Case submissions: hemehub.org/case-submiss...

#MultipleMyeloma #Hematology #Oncology
@mskcancercenter.bsky.social @utswim.bsky.social

Is CAR T-cell therapy right for multiple myeloma?

Learn about candidates, risks, outcomes, and quality of life after treatment.

🗓 May 6
🕐 1:15p ET | 12:15p CT | 11:15a MT | 10:15a PT

Register: bmtinfonet.org/registration...

#CARTCellTherapy #MultipleMyeloma #BMTInfoNet #CancerSurvivorship

The study characterizes the TME in EMM lesions and paired BM from patients with #multiplemyeloma, revealing a high proportion of less cytotoxic CD16− NK cells in EMM tumors and suggesting that direct cell–cell interactions may underlie the CD8+ T-cell exhaustion observed in a subset of these tumors.

Sickle Cell Disease: From Diagnosis to Cure by #MelissaFreiJones: ASPHO is proud to partner with Mediaplanet in the Blood Health supplement in USA TODAY 3/25-27. #BloodDisorder—including #blood #cancers #leukemia #lymphoma #multiplemyeloma #research uthealthsa.bsky.social

Bloodlines Series: What Is Smoldering Myeloma? Learn what is smoldering myeloma and about the first treatment approved by the FDA to prevent its progression to active multiple myeloma.

Early treatment for high risk #SmolderingMyeloma is no longer hypothetical—it’s FDA approved. Now #ClinicalTrials like EAA173 (DETER SMM) are critical to determine who benefits most and how much treatment is enough. Learn more about #SMM: bit.ly/4bVbJdk #MultipleMyeloma

Canada you made Myeloma Action Month shine! We are all part of the global movement to create a brighter future for people living with myeloma.
#MyelomaActionMonth #MoreThanMyeloma #MyelomaAwarenessMonth #MyelomaCanada #MyélomeCanada #MultipleMyeloma #MyélomeMultiple #MoisActionMyélome

For Myeloma Action Month., we translated 6 key studies from #ASH2025 into plain language:
https://ow.ly/ttl350YuwxH

Each summary is 2 pages & includes a box of questions to ask your doctor.

Thank you to the International Myeloma Foundation for your work!

#MultipleMyeloma #SmartPatients

Read this recent study from Blood Cancer Discovery: CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk #MultipleMyeloma Models buff.ly/QUyjauh

Multiple myeloma isn’t the end of options, it’s the start of smarter ones.

Curious about your options?

www.placidway.com/article/6632/Multiple-My...

#MultipleMyeloma #CancerCare #Immunotherapy #PatientOptions #GlobalHealthcare

March is #MyelomaActionMonth

Dr. Joe Mikhael, professor at TGen, shares how TGen is working to improve patient care for those diagnosed with #MultipleMyeloma.

#TGen #Research

Global MM incidence in AYA increased 60% (1990-2021), with males experiencing 43% higher rates and widening health inequalities. Read in Blood Global Hematology: ow.ly/Mqaw50YsxP1 #MultipleMyeloma

✅️ Apply evidence from landmark trials to myeloma treatment sequencing
✅️ Navigate emerging immunotherapies including CAR T-cell therapies and bispecific antibodies
✅️ Identify the role of novel agents such as antibody-drug conjugates in relapsed and refractory settings

#MultipleMyeloma #Oncology

ASH produces some of the most important findings in blood cancer research. After ASH 2025, we translated 6 studies into plain-language summaries for community discussion. Patients want the data and to understand what it means for treatment. https://ow.ly/ttl350YuwxH

#BloodCancer #MultipleMyeloma

Teclistamab + Daratumumab Hyaluronidase-fihj Approved for R/R Multiple Myeloma - Oncology Nurse Advisor Findings from MajesTEC-3 support the approval of teclistamab plus daratumumab for patients with refractory multiple myeloma and prior lenalidomide use.

The FDA has approved teclistamab in combo with daratumumab hyaluronidase-fihj for adult patients with R/R #multipleMyeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. From @medicalprofref.bsky.social.

https://bit.ly/4rtYpCe

Test Your Knowledge: The @ascopost.bsky.social has partnered with @ontariohealth.bsky.social to issue a series of guidelines regarding the management of #multipleMyeloma.

https://bit.ly/4sEqGqD

#myeloma #ClinicalQuiz

First-line Therapy in Newly Diagnosed Multiple Myeloma AbstractFirst-line multiple myeloma treatment has evolved from melphalan–prednisone to quadruplet regimens incorporating proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal…

Despite unprecedented advances, #multiplemyeloma therapy remains largely uniform and emphasizes indefinite treatment. Herein, the authors advocate for individualized approaches informed by disease biology, treatment response, and emerging biomarkers. Learn more: buff.ly/dDefeBV

Carvykti, una terapia CAR-T desarrollada en China, está creciendo rápidamente en el mercado global 🌍

Las ventas alcanzaron $1.887B en el tratamiento del mieloma múltiple 📈

¿Cómo logró crecer tan rápido?
Mira el video 🔽

#Carvykti #CART #MultipleMyeloma #Oncology #Biotech

Famous one being #Thalidomide in a specific tragic error of judgement. Still in use in #NHS it now treats #multiplemyeloma by strengthening immune system to fight #cancer cells.

For my generation; it's a haunting spectre; the likes of #VictoriaAtkins exploited it with her unnecessary emergency ban.

Read the new review in Blood Cancer Discovery, "Rethinking #MultipleMyeloma Treatment: The Biological and Clinical Insights Guiding Immune-Based Combinations." buff.ly/Z0lDiYe

ONCOassist Universal Link Opening ONCOassist app...

🔷 This marks the first positive Phase III trial for the oral CELMoD Mezigdomide, with a safety profile consistent with prior studies.

🔗 Read more: bit.ly/ONCOnews10Ma...

#ONCOnews #OncoAlert #OncEd #MultipleMyeloma #Hematology #Oncology #CancerResearch #ClinicalTrials #Phase3Trial

BMS eyes another celmod filing in myeloma after phase 3 win Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.

#BristolMyersSquibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted #celmod development programme for #multiplemyeloma.

➡️Join us Wed. 11th March 12:30pm at CIPF #FBRLectureSeries Conference with Alexandre Detappe, distinctive researcher in chemistry, medical physics, biomedical engineering & design of nanotherapeutic systems for #oncology #nanoimmunotherapy #multiplemyeloma
cipf.es/news-society...

💊FDA Approval Update | #TECVAYLI (#teclistamab-cqyv) and #DARZALEX FASPRO (#daratumumab and #hyaluronidase-fihj)
🌟For adults with relapsed/refractory multiple myeloma after ≥1 prior therapy
🌟Significantly reduced the risk of disease progression or death
#MultipleMyeloma #Immunotherapy

#JohnsonandJohnson's #Tecvayli has been approved as part of a #combinationregimen with its #Genmab-partnered #DarzalexFaspro as a second-line therapy for relapsed or refractory #multiplemyeloma, just 55 days after it was filed with the FDA.

pharmaphorum.com/news/jjs-tec...

Researchers at Beth Israel map new pathways to treat multiple myeloma, a complex blood cancer - Boston Business Journal Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer Society.

Is a custom vaccine for #multiplemyeloma on the horizon? 🧬

Researchers at BIDMC are working to uncover how myeloma progresses and how personalized, immune-based vaccines could help target each patient’s cancer. Read more⤵️
bit.ly/4b8WmgM

📝 @bosbizjournal.bsky.social

How does MRD influence treatment decisions in blood cancers?

Hannah Levavi explains how measurable residual disease is used in ALL and multiple myeloma, with clear examples for patients and caregivers.

Watch the full video:
youtu.be/O5GF4hEAPuc

#Hematology #MRD #Leukemia #MultipleMyeloma

Infections are a major concern in multiple myeloma.

In this video, Hamza Hashmi covers infection risk factors in MM and key prevention strategies: hygiene, prophylaxis, IVIG, and vaccination.

Watch here: youtu.be/Q4Yri4vn1_A

#MultipleMyeloma #Hematology #Oncology

Hey Canada! Show us your life lit up red for Myeloma Action Month! Visit MYELOMA.CA for details!
#MyelomaActionMonth #MoreThanMyeloma #MyelomaAwarenessMonth #MyelomaCanada #MyélomeCanada #MultipleMyeloma #MyélomeMultiple #PlusQueMyélome #MoisActionMyélome

Canada, mettons le rouge à l’honneur à l’occasion du Mois de l’action pour le myélome! Rendez‑vous sur MYELOME.CA pour les détails!
#MyelomaActionMonth #MoreThanMyeloma #MyelomaAwarenessMonth #MyelomaCanada #MyélomeCanada #MultipleMyeloma #MyélomeMultiple #PlusQueMyélome #MoisActionMyélome

On #RareDiseaseDay, we highlight how #SYNTHIA supports research in rare cancers. Using #syntheticdata, our work in #multiplemyeloma and #DLBCL strengthens clinical trials and improves outcome prediction.
#PersonalisedMedicine #HealthInnovation #EUResearch #IHITransformingHealth #HorizonEU